Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 23, 2008
Grant Date -
Oct 5, 2006
app pub date -
Jul 12, 2004
filing date -
Jul 14, 2003
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The invention describes for the first time the preclinical/cellular and clinical relevance of VIP, PACAP as well as of substances with the same biological activity as VIP and PACAP for the treatment of interstitial lung infections such as idiopathic pulmonary fibrosis, hypersensitive pneumonia or diffused panbronchiolitis. VIP and PACAP are synthesised in different areas of the central nervous system, e.g. in specific cerebral areas such as the hippocampus and the cortex, as well as in the peripheral ganglia. VIP is also released by immune cells.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully